Patents by Inventor Luigi Ferrucci

Luigi Ferrucci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200347461
    Abstract: Identifying reliable biomarkers of aging is a major goal in geroscience. While the first generation of epigenetic biomarkers of aging were developed using chronological age as a surrogate for biological age, we hypothesized that composite clinical measures of “phenotypic age”, may facilitate the development of a more powerful epigenetic biomarker of aging. Here we show that our newly developed epigenetic biomarker of aging “DNAm PhenoAge” strongly outperforms previous measure in regards to predictions for a variety of aging outcomes, including all-cause mortality, cancers, physical functioning, and, age-related dementia. It is also associated with Down syndrome, HIV infection, socioeconomic status, and various life style factors such as diet, exercise, and smoking. Overall, this single epigenetic biomarker of aging is able to capture risks for an array of diverse outcomes across multiple tissues and cells, and in moving forward, will facilitate the development of anti-aging interventions.
    Type: Application
    Filed: January 17, 2019
    Publication date: November 5, 2020
    Applicants: The Regents of the University of California, National Institutes of Health
    Inventors: Stefan Horvath, Morgan E. Levine, Luigi Ferrucci
  • Publication number: 20100150838
    Abstract: Methods are provided for evaluating osteoarthritis (OA), for example for diagnosing OA, to confirm a diagnosis of OA, to assess or prognose progression of OA, determining the severity of a subject who has OA, and determining a subject's risk of developing OA in the future, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes determining an amount of activity (such as an amount of protein present or an amount of expression) of OA risk-related molecules, such as soluble vascular adhesion protein 1 (sVAP-1) or interleukin-15 (IL-15). Also provided are methods of identifying one or more compounds that alter the activity of an OA-related molecule, thereby identifying potential anti-osteoarthritis drugs.
    Type: Application
    Filed: December 24, 2009
    Publication date: June 17, 2010
    Inventors: Shari M. Ling, Lorah Perlee, Velizar T. Tchernev, Serguei Lejnine, Dhavalkumar D. Patel, Luigi Ferrucci, Ming Zhan
  • Patent number: 7662573
    Abstract: Methods are provided for evaluating osteoarthritis (OA), for example for diagnosing OA, to confirm a diagnosis of OA, to assess or prognose progression of OA, determining the severity of a subject who has OA, and determining a subject's risk of developing OA in the future, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes determining an amount of activity (such as an amount of protein present or an amount of expression) of OA risk-related molecules, such as soluble vascular adhesion protein 1 (sVAP-1) or interleukin-15 (IL-15). Also provided are methods of identifying one or more compounds that alter the activity of an OA-related molecule, thereby identifying potential anti-osteoarthritis drugs.
    Type: Grant
    Filed: August 12, 2005
    Date of Patent: February 16, 2010
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Shari M. Ling, Lorah Perlee, Velizar T. Tchernev, Serguei Lejnine, Dhavalkumar D. Patel, Luigi Ferrucci, Ming Zhan
  • Publication number: 20070225206
    Abstract: Methods are provided for evaluating osteoarthritis (OA), for example for diagnosing OA, to confirm a diagnosis of OA, to assess or prognose progression of OA, determining the severity of a subject who has OA, and determining a subject's risk of developing OA in the future, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes determining an amount of activity (such as an amount of protein present or an amount of expression) of OA risk-related molecules, such as soluble vascular adhesion protein 1 (sVAP-1) or interleukin-15 (IL-15). Also provided are methods of identifying one or more compounds that alter the activity of an OA-related molecule, thereby identifying potential anti-osteoarthritis drugs.
    Type: Application
    Filed: August 12, 2005
    Publication date: September 27, 2007
    Inventors: Shari Ling, Lorah Perlee, Velizar Tchernev, Serguei Lejnine, Dhavalkumar Patel, Luigi Ferrucci, Ming Zhan